Standard BioTools Inc
NASDAQ:LAB

Watchlist Manager
Standard BioTools Inc Logo
Standard BioTools Inc
NASDAQ:LAB
Watchlist
Price: 1.08 USD 2.86%
Market Cap: 409.3m USD

Wall Street
Price Targets

LAB Price Targets Summary
Standard BioTools Inc

Wall Street analysts forecast LAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LAB is 2.42 USD with a low forecast of 2.27 USD and a high forecast of 2.63 USD.

Lowest
Price Target
2.27 USD
110% Upside
Average
Price Target
2.42 USD
124% Upside
Highest
Price Target
2.63 USD
143% Upside
Standard BioTools Inc Competitors:
Price Targets
PSNL
Personalis Inc
51% Upside
603127
Joinn Laboratories China Co Ltd
19% Upside
ADPT
Adaptive Biotechnologies Corp
28% Upside
SHC
Sotera Health Co
21% Upside
QGEN
Qiagen NV
18% Upside
ABSI
Absci Corp
223% Upside
VIMTALABS
Vimta Labs Ltd
43% Downside
300463
Maccura Biotechnology Co Ltd
16% Upside

Revenue
Forecast

Revenue Estimate
Standard BioTools Inc

For the last 8 years the compound annual growth rate for Standard BioTools Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

7%
Past Growth
6%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Standard BioTools Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
Standard BioTools Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-83%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LAB's stock price target?
Price Target
2.42 USD

According to Wall Street analysts, the average 1-year price target for LAB is 2.42 USD with a low forecast of 2.27 USD and a high forecast of 2.63 USD.

What is Standard BioTools Inc's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Standard BioTools Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

Back to Top